Erbitux (cetuximab)

Adagrasib monotherapy yielded a median PFS of 4.4-5.6 months, an OS of 10-19.8 months, and an ORR of 19-23%, while its combination with cetuximab reported a PFS of 6.9 months, an OS of 13.4-15.9 months and an ORR of 34-46%...When combined with panitumumab, 960 mg sotorasib demonstrated better results with a PFS of 5.6-5.7 months, OS of 15.2 months and an ORR of 12.5-30%. Similarly, divarasib monotherapy led to a PFS of 5.6-6.9 months and an ORR of 20%, while its combination with cetuximab resulted in a PFS of 8.1 months and an ORR of 62.5%. Combination therapy of olomorasib and MK-1084, which are new-generation KRAS p.G12C (c.34G > T) inhibitors, with cetuximab also demonstrated highly promising efficacy with ORR of 38-44% and 50%, respectively...Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.

The clinical course and histologic features, including a reproducible eruption upon re-exposure, were strongly consistent with a drug-induced type IV hypersensitivity reaction, supporting the diagnosis. This case underscores the importance of recognizing delayed cutaneous adverse reactions when considering treatment interruption and re-challenge during prolonged or intermittent cetuximab therapy.

P1/2, N=542, Recruiting, Sanofi | Not yet recruiting --> Recruiting

P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

P2, N=43, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | N=24 --> 43

As a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.

Common events such as rash and dermatitis acneiform, as well as several less frequently described reactions, warrant heightened clinical vigilance, especially in older and male patients. Prospective and mechanistic studies are needed to confirm these associations and to refine strategies for preventing and managing cetuximab-induced skin toxicity.

P2, N=90, Not yet recruiting, Chinese PLA General Hospital

P1, N=237, Active, not recruiting, Quanta Therapeutics | Recruiting --> Active, not recruiting

P3, N=454, Not yet recruiting, NRG Oncology

P1, N=681, Recruiting, Astellas Pharma Inc | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2026 --> Dec 2027

Residual tumors after near-infrared photoimmunotherapy can occur despite adequate laser irradiation and epidermal growth factor receptor expression. Our observations imply that insufficient immune activation within the tumor microenvironment may contribute to treatment resistance. Further characterization of the post-photoimmunotherapy tumor microenvironment will be essential to better understand treatment mechanisms and to optimize therapeutic efficacy.